Payment & Shipping Terms:
1378388 16 9,
1438383 89 1
CAS : 1335316-40-9 Velpatasvir Intermediate C13H22N2O5 99.0% Min cGMP standard
Chemical Name : ( 5S ) - N - ( Methoxycarbonyl ) - L - valyl - 5 - methyl - L - proline
CAS No . : 1335316-40-9
Molecular Formula : C13H22N2O5
Molecular Weight : 286.32
Usage : Velpatasvir Intermediate
Velpatasvir is innovated by Gilead to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used together with Sofosbuvir. The mechanism of action is as a Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Anion Transporting Polypeptide 2B1 Inhibitor. It blocks NS5A, a protein necessary for hepatitis C virus replication assembly.
( 5S ) - N - ( Methoxycarbonyl ) - L - valyl - 5 - methyl - L - proline CAS No . : 1335316-40-9 is an advanced intermediate of velpatasvir. There might be several synthesis routes to manufacture this intermediate but some routes or compounds are protected by the patents in some countries and regions. We strictly obey the laws and our products will not be sold to those areas protected by patents for commercial purposes. Anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.